BMC Cancer · 2011 · 72 citations · 22 references
MedicineCancer BiologyOncologyBreast OncologyComparative OncologySurgical OncologyBreast Cancer OncologyHer2-positive Breast CancerMale Breast CancerBreast Cancer Molecular SubtypesHer2 AmplificationHer2 ExpressionMale Breast TumorsProgesterone ReceptorsTumor Stage Prognosis
BACKGROUND: Male breast cancer (MBC) is a rare disease accounting for approximately 1% of all breast carcinomas. Presently treatment recommendations are derived from the standards for female breast cancer. However, those approaches might be inadequate because of distinct gender specific differences in tumor biology of breast cancer. This study was planned in order to contrast potential differences between female and male breast cancer in both tumor biological behavior and clinical management. METHODS: MBC diagnosed between 1995-2007 (region Chemnitz/Zwickau, Saxony, Germany) was retrospectively analyzed. Tumor characteristics, treatment and follow-up of the patients were documented. In order to highlight potential differences each MBC was matched with a female counterpart (FBC) that showed accordance in at least eight tumor characteristics (year of diagnosis, age, tumor stage, nodal status, grade, estrogen- and progesterone receptors, HER2 status). RESULTS: 108 male/female matched-pairs were available for survival analyses. In our study men and women with breast cancer had similar disease-free (DFS) and overall (OS) survival. The 5-years DFS was 53.4% (95% CI, range 54.1-66.3) in men respectively 62.6% (95% CI, 63.5-75.3) in women (p > 0.05). The 5-years OS was 71.4% (95% CI, 62.1-72.7%) and 70.3% (95% CI, 32.6-49.6) in women (p > 0.05). In males DFS analyses revealed progesterone receptor expression as the only prognostic relevant factor (p = 0.006). In multivariate analyses for OS both advanced tumor size (p = 0.01) and a lack of progesterone receptor expression were correlated (p = 0.01) with poor patients outcome in MBC. CONCLUSION: Our comparative study revealed no survival differences between male and female breast cancer patients and gives evidence that gender is no predictor for survival in breast cancer. This was shown despite of significant gender specific differences in terms of frequency and intensity of systemic therapy in favor to female breast cancer.
22
Ahmedin Jemal, Rebecca L. Siegel, Elizabeth Ward et al. · CA A Cancer Journal for Clinicians · 2008 · 10.2K citations · Full text
Male Breast Cancer: A Population-Based Comparison With Female Breast Cancer
William F. Anderson, Ismail Jatoi, Julia Tse et al. · Journal of Clinical Oncology · 2009 · 489 citations · Full text
Medicine, Cancer Biology, Oncology +15
Current Management of Male Breast Cancer
Patrick I. Borgen, George Y. Wong, Vaia Vlamis et al. · Annals of Surgery · 1992 · 201 citations · Full text